Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition
Medical research is at the forefront of addressing pressing global challenges, including preventing and treating cardiovascular, autoimmune, and oncological diseases, neurodegenerative disorders, and the growing resistance of pathogens to antibiotics. Understanding the molecular mechanisms underlyin...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/6/783 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849704933707743232 |
|---|---|
| author | Antónia Kurillová Libor Kvítek Aleš Panáček |
| author_facet | Antónia Kurillová Libor Kvítek Aleš Panáček |
| author_sort | Antónia Kurillová |
| collection | DOAJ |
| description | Medical research is at the forefront of addressing pressing global challenges, including preventing and treating cardiovascular, autoimmune, and oncological diseases, neurodegenerative disorders, and the growing resistance of pathogens to antibiotics. Understanding the molecular mechanisms underlying these diseases, using advanced medical approaches and cutting-edge technologies, structure-based drug design, and personalized medicine, is critical for developing effective therapies, specifically anticancer treatments. <b>Background/Objectives</b>: One of the key drivers of cancer at the cellular level is the abnormal activity of protein enzymes, specifically serine, threonine, or tyrosine residues, through a process known as phosphorylation. While tyrosine kinase-mediated phosphorylation constitutes a minor fraction of total cellular phosphorylation, its dysregulation is critically linked to carcinogenesis and tumor progression. <b>Methods</b>: Small-molecule inhibitors, such as imatinib or erlotinib, are designed to halt this process, restoring cellular equilibrium and offering targeted therapeutic approaches. However, challenges persist, including frequent drug resistance and severe side effects associated with these therapies. Nanomedicine offers a transformative potential to overcome these limitations. <b>Results</b>: By leveraging the unique properties of nanomaterials, it is possible to achieve precise drug delivery, enhance accumulation at target sites, and improve therapeutic efficacy. Examples include nanoparticle-based delivery systems for TKIs and the combination of nanomaterials with photothermal or photodynamic therapies to enhance treatment effectiveness. Combining nanomedicine with traditional treatments holds promise and perspective for synergistic and more effective cancer management. <b>Conclusions</b>: This review delves into recent advances in understanding tyrosine kinase activity, the mechanisms of their inhibition, and the innovative integration of nanomedicine to revolutionize cancer treatment strategies. |
| format | Article |
| id | doaj-art-9e4ff5dc93b245c3bd5faa71279f3e6e |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-9e4ff5dc93b245c3bd5faa71279f3e6e2025-08-20T03:16:35ZengMDPI AGPharmaceutics1999-49232025-06-0117678310.3390/pharmaceutics17060783Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase InhibitionAntónia Kurillová0Libor Kvítek1Aleš Panáček2Department of Physical Chemistry, Faculty of Science, Palacký University in Olomouc, 17. Listopadu 12, 77900 Olomouc, Czech RepublicDepartment of Physical Chemistry, Faculty of Science, Palacký University in Olomouc, 17. Listopadu 12, 77900 Olomouc, Czech RepublicDepartment of Physical Chemistry, Faculty of Science, Palacký University in Olomouc, 17. Listopadu 12, 77900 Olomouc, Czech RepublicMedical research is at the forefront of addressing pressing global challenges, including preventing and treating cardiovascular, autoimmune, and oncological diseases, neurodegenerative disorders, and the growing resistance of pathogens to antibiotics. Understanding the molecular mechanisms underlying these diseases, using advanced medical approaches and cutting-edge technologies, structure-based drug design, and personalized medicine, is critical for developing effective therapies, specifically anticancer treatments. <b>Background/Objectives</b>: One of the key drivers of cancer at the cellular level is the abnormal activity of protein enzymes, specifically serine, threonine, or tyrosine residues, through a process known as phosphorylation. While tyrosine kinase-mediated phosphorylation constitutes a minor fraction of total cellular phosphorylation, its dysregulation is critically linked to carcinogenesis and tumor progression. <b>Methods</b>: Small-molecule inhibitors, such as imatinib or erlotinib, are designed to halt this process, restoring cellular equilibrium and offering targeted therapeutic approaches. However, challenges persist, including frequent drug resistance and severe side effects associated with these therapies. Nanomedicine offers a transformative potential to overcome these limitations. <b>Results</b>: By leveraging the unique properties of nanomaterials, it is possible to achieve precise drug delivery, enhance accumulation at target sites, and improve therapeutic efficacy. Examples include nanoparticle-based delivery systems for TKIs and the combination of nanomaterials with photothermal or photodynamic therapies to enhance treatment effectiveness. Combining nanomedicine with traditional treatments holds promise and perspective for synergistic and more effective cancer management. <b>Conclusions</b>: This review delves into recent advances in understanding tyrosine kinase activity, the mechanisms of their inhibition, and the innovative integration of nanomedicine to revolutionize cancer treatment strategies.https://www.mdpi.com/1999-4923/17/6/783nanomaterialsmetal nanoparticlesgold nanoparticlesnanomedicinetyrosine kinase inhibitorsdrug delivery |
| spellingShingle | Antónia Kurillová Libor Kvítek Aleš Panáček Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition Pharmaceutics nanomaterials metal nanoparticles gold nanoparticles nanomedicine tyrosine kinase inhibitors drug delivery |
| title | Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition |
| title_full | Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition |
| title_fullStr | Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition |
| title_full_unstemmed | Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition |
| title_short | Innovative Approaches in Cancer Treatment: Emphasizing the Role of Nanomaterials in Tyrosine Kinase Inhibition |
| title_sort | innovative approaches in cancer treatment emphasizing the role of nanomaterials in tyrosine kinase inhibition |
| topic | nanomaterials metal nanoparticles gold nanoparticles nanomedicine tyrosine kinase inhibitors drug delivery |
| url | https://www.mdpi.com/1999-4923/17/6/783 |
| work_keys_str_mv | AT antoniakurillova innovativeapproachesincancertreatmentemphasizingtheroleofnanomaterialsintyrosinekinaseinhibition AT liborkvitek innovativeapproachesincancertreatmentemphasizingtheroleofnanomaterialsintyrosinekinaseinhibition AT alespanacek innovativeapproachesincancertreatmentemphasizingtheroleofnanomaterialsintyrosinekinaseinhibition |